Masson W, Lobo M, Masson G, et al. - By analyzing relevant randomized trials in this meta-analysis, researchers assessed the liver safety as well as cardiovascular advantage in relation to statin-based lipid-lowering treatment vs a less intensive treatment or placebo in people with abnormal liver tests at baseline. They identified five eligible trials, comprising 2,548 patients. A comparable incidence of worsening transaminases levels was reported in relation to a more intensive statin-based lipid-lowering treatment vs less intensive treatment or placebo, in individuals with abnormal liver tests at baseline. In addition, the use of a more intensive lipid-lowering therapy was associated with a decrease in cardiovascular events.